Gastrointestinal reported outcomes following one anastomosis gastric bypass based on a multicenter study

ABSTRACT

Objectives

To describe gastrointestinal-related side-effects reported following the One Anastomosis Gastric Bypass (OAGB).

Methods

A multicenter study among OAGB patients across Israel (n = 277) and Portugal (n = 111) who were recruited to the study based on time elapsed since surgery was performed. An online survey with information on demographics, anthropometrics, medical conditions, and gastrointestinal outcomes was administered in both countries simultaneously.

Results

Respondents from Israel (pre-surgery age of 41.6 ± 11.0 years, 75.8% females) and Portugal (pre-surgery age of 45.6 ± 12.3 years, 79.3% females) presented mean excess weight loss of 51.0 ± 19.9 and 62.4 ± 26.5%, 89.0 ± 22.0 and 86.2 ± 21.4%, and 89.9 ± 23.6 and 98.2 ± 20.9% (P < 0.001 for both countries), at 1–6 months, 6–12 months, and 1–5 years post-surgery, respectively. Median Gastrointestinal Symptom Rating Scale score was similar between time elapsed since surgery groups among respondents from Israel and Portugal (≤1.97 and ≤2.12). A notable proportion of respondents from Israel and Portugal at all time points reported 1–3 bowel movements per day (≤62.8 and ≤87.6%), Bristol stool scale categories which represent diarrhea-like stools (≤51.9 and ≤56.3%), having discomfort due to flatulence (≤79.4 and ≤90.2%), and mild to severe dyspepsia symptoms (≤50.5 and ≤73.0%).

Conclusions

A notable proportion of OAGB patients might experience certain gastrointestinal symptoms postoperatively, including flatulence, dyspepsia, and diarrhea-like stools.

KEYWORDS:

• Bariatric surgery
• functional gastrointestinal disorders
• gastric bypass
• obesity
• weight outcomes

Acknowledgments

We thank Mary O’Kane (UK) for her advice regarding the construction of the research survey.

Declaration of interest

RR was paid honoraria for teaching or discussion sessions about OAGB by Ethicon and Medtronic. KM has been paid honoraria by several NHS Trusts, Ethicon Inc, Medtronic Inc, Gore Inc, and Olympus Inc for educational activities related to OAGB. All other authors declare that there is no conflict of interest.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Data availability statement

The data that support the findings of this study are available from the corresponding author, [RB], upon reasonable request.

Ethics statement

This study was reviewed and approved by the Assuta Medical Center Institutional Ethics Committee-#0104–19-ASMC (Israel), and the Clínica de Santo António Ethics Committee (Portugal).

Author contribution statement

The authors’ responsibilities were as follows – SSD, RB, RR, TBP, KM, and YG designed the research; RB, SSD, YK, AR, HK, NS, DG, RR, CR, RB, ZS, and OV performed the research; SSD and RB analyzed the data; and SSD, RB, and TBP wrote the manuscript. All authors read and approved the final manuscript.

Supplementary Material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/17474124.2023.2211766

Additional information

Funding

This study was supported (in part) by an independent grant from Celebrate Nutritional Supplements. The funder was not involved in the study design, collecting, and analyzing the data, writing the report, and submitting this paper for publication